SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Idorsia to Advance Daridorexant in Autism Program

Idorsia plans to pursue daridorexant development for autism spectrum disorder, citing exploratory improvements beyond sleep in a pediatric study. Program details are expected in H1 2027 after health authority discussions.

IDIA

Related stories